Alpine Partners VI LLC bought a new position in Genocea Biosciences Inc. (NASDAQ:GNCA) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 29,169 shares of the company’s stock, valued at approximately $120,000.
Other hedge funds also recently bought and sold shares of the company. Schonfeld Strategic Advisors LLC bought a new stake in Genocea Biosciences during the first quarter worth $565,000. State Street Corp boosted its stake in Genocea Biosciences by 11.9% in the first quarter. State Street Corp now owns 291,020 shares of the company’s stock worth $2,256,000 after buying an additional 30,920 shares during the last quarter. Franklin Resources Inc. boosted its stake in Genocea Biosciences by 37.0% in the first quarter. Franklin Resources Inc. now owns 2,886,600 shares of the company’s stock worth $22,342,000 after buying an additional 779,400 shares during the last quarter. Geode Capital Management LLC boosted its stake in Genocea Biosciences by 1.3% in the first quarter. Geode Capital Management LLC now owns 136,990 shares of the company’s stock worth $1,060,000 after buying an additional 1,743 shares during the last quarter. Finally, TFS Capital LLC bought a new stake in Genocea Biosciences during the second quarter worth $133,000. 56.49% of the stock is currently owned by hedge funds and other institutional investors.
Genocea Biosciences Inc. (NASDAQ:GNCA) opened at 4.09 on Monday. The company has a 50-day moving average of $5.26 and a 200 day moving average of $4.72. Genocea Biosciences Inc. has a 12-month low of $2.56 and a 12-month high of $8.20. The firm’s market cap is $115.89 million.
Genocea Biosciences (NASDAQ:GNCA) last posted its earnings results on Thursday, August 4th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.44) by $0.05. Genocea Biosciences had a negative net margin of 5,121.17% and a negative return on equity of 47.87%. Equities analysts expect that Genocea Biosciences Inc. will post ($1.63) EPS for the current fiscal year.
A number of equities analysts have recently commented on the stock. FBR & Co reiterated a “buy” rating and set a $17.00 price target on shares of Genocea Biosciences in a report on Wednesday, October 5th. Needham & Company LLC reiterated a “buy” rating and set a $15.00 price target on shares of Genocea Biosciences in a report on Thursday, September 29th. Zacks Investment Research upgraded shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a report on Tuesday, July 5th. Finally, Piper Jaffray Cos. cut their price target on shares of Genocea Biosciences from $9.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, September 29th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $12.35.
About Genocea Biosciences
Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.
Want to see what other hedge funds are holding GNCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genocea Biosciences Inc. (NASDAQ:GNCA).
Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.